Aesculap Biologics Announces NOVOCART 3D Trial Enrollment Milestone
Aesculap Biologics achieved 50% enrollment in its Phase III clinical trial of NOVOCART® 3D, an autologous chondrocyte transplantation system to treat articular cartilage defects in the knee. Mar 04, 2019